Literature DB >> 29802206

Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation.

Chunxia Yao1,2,3, Tina Veleva4, Larry Scott1,2,5, Shuyi Cao1,5, Luge Li2, Gong Chen2, Prince Jeyabal1,2, Xiaolu Pan1,5, Katherina M Alsina6, Issam Abu-Taha4, Shokoufeh Ghezelbash4, Corey L Reynolds5,7, Ying H Shen1,8, Scott A LeMaire1,8, Wilhelm Schmitz9, Frank U Müller9, Ali El-Armouche10, N Tony Eissa11, Christine Beeton5, Stanley Nattel4,12, Xander H T Wehrens1,5,13,14,15, Dobromir Dobrev4, Na Li1,2,5.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is frequently associated with enhanced inflammatory response. The NLRP3 (NACHT, LRR, and PYD domain containing protein 3) inflammasome mediates caspase-1 activation and interleukin-1β release in immune cells but is not known to play a role in cardiomyocytes (CMs). Here, we assessed the role of CM NLRP3 inflammasome in AF.
METHODS: NLRP3 inflammasome activation was assessed by immunoblot in atrial whole-tissue lysates and CMs from patients with paroxysmal AF or long-standing persistent (chronic) AF. To determine whether CM-specific activation of NLPR3 is sufficient to promote AF, a CM-specific knockin mouse model expressing constitutively active NLRP3 (CM-KI) was established. In vivo electrophysiology was used to assess atrial arrhythmia vulnerability. To evaluate the mechanism of AF, electric activation pattern, Ca2+ spark frequency, atrial effective refractory period, and morphology of atria were evaluated in CM-KI mice and wild-type littermates.
RESULTS: NLRP3 inflammasome activity was increased in the atrial CMs of patients with paroxysmal AF and chronic AF. CM-KI mice developed spontaneous premature atrial contractions and inducible AF, which was attenuated by a specific NLRP3 inflammasome inhibitor, MCC950. CM-KI mice exhibited ectopic activity, abnormal sarcoplasmic reticulum Ca2+ release, atrial effective refractory period shortening, and atrial hypertrophy. Adeno-associated virus subtype-9-mediated CM-specific knockdown of Nlrp3 suppressed AF development in CM-KI mice. Finally, genetic inhibition of Nlrp3 prevented AF development in CREM transgenic mice, a well-characterized mouse model of spontaneous AF.
CONCLUSIONS: Our study establishes a novel pathophysiological role for CM NLRP3 inflammasome signaling, with a mechanistic link to the pathogenesis of AF, and establishes the inhibition of NLRP3 as a potential novel AF therapy approach.

Entities:  

Keywords:  AAV9; NLRP3 inflammasome; atrial fibrillation; electrical remodeling

Mesh:

Substances:

Year:  2018        PMID: 29802206      PMCID: PMC6252285          DOI: 10.1161/CIRCULATIONAHA.118.035202

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  76 in total

1.  The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury.

Authors:  Øystein Sandanger; Trine Ranheim; Leif Erik Vinge; Marte Bliksøen; Katrine Alfsnes; Alexandra V Finsen; Christen P Dahl; Erik T Askevold; Geir Florholmen; Geir Christensen; Katherine A Fitzgerald; Egil Lien; Guro Valen; Terje Espevik; Pål Aukrust; Arne Yndestad
Journal:  Cardiovasc Res       Date:  2013-04-10       Impact factor: 10.787

2.  Unified polymerization mechanism for the assembly of ASC-dependent inflammasomes.

Authors:  Alvin Lu; Venkat Giri Magupalli; Jianbin Ruan; Qian Yin; Maninjay K Atianand; Matthijn R Vos; Gunnar F Schröder; Katherine A Fitzgerald; Hao Wu; Edward H Egelman
Journal:  Cell       Date:  2014-03-13       Impact factor: 41.582

Review 3.  Anti-inflammatory therapies for cardiovascular disease.

Authors:  Paul M Ridker; Thomas F Lüscher
Journal:  Eur Heart J       Date:  2014-05-26       Impact factor: 29.983

4.  Inhibition of CaMKII phosphorylation of RyR2 prevents induction of atrial fibrillation in FKBP12.6 knockout mice.

Authors:  Na Li; Tiannan Wang; Wei Wang; Michael J Cutler; Qiongling Wang; Niels Voigt; David S Rosenbaum; Dobromir Dobrev; Xander H T Wehrens
Journal:  Circ Res       Date:  2011-12-08       Impact factor: 17.367

5.  Role for NLRP3 Inflammasome-mediated, IL-1β-Dependent Responses in Severe, Steroid-Resistant Asthma.

Authors:  Richard Y Kim; James W Pinkerton; Ama T Essilfie; Avril A B Robertson; Katherine J Baines; Alexandra C Brown; Jemma R Mayall; M Khadem Ali; Malcolm R Starkey; Nicole G Hansbro; Jeremy A Hirota; Lisa G Wood; Jodie L Simpson; Darryl A Knight; Peter A Wark; Peter G Gibson; Luke A J O'Neill; Matthew A Cooper; Jay C Horvat; Philip M Hansbro
Journal:  Am J Respir Crit Care Med       Date:  2017-08-01       Impact factor: 21.405

6.  Assessment of interleukin-1 gene cluster polymorphisms in lone atrial fibrillation: new insight into the role of inflammation in atrial fibrillation.

Authors:  Baris Gungor; Ahmet Ekmekci; Ahmet Arman; Kazim S Ozcan; Ekrem Ucer; Ahmet T Alper; Nazmi Calik; Hale Yilmaz; Tuna Tezel; Ajda Coker; Osman Bolca
Journal:  Pacing Clin Electrophysiol       Date:  2013-05-28       Impact factor: 1.976

7.  Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability.

Authors:  Toru Oka; Marjorie Maillet; Alistair J Watt; Robert J Schwartz; Bruce J Aronow; Stephen A Duncan; Jeffery D Molkentin
Journal:  Circ Res       Date:  2006-03-02       Impact factor: 17.367

8.  Mutation E169K in junctophilin-2 causes atrial fibrillation due to impaired RyR2 stabilization.

Authors:  David L Beavers; Wei Wang; Sameer Ather; Niels Voigt; Alejandro Garbino; Sayali S Dixit; Andrew P Landstrom; Na Li; Qiongling Wang; Iacopo Olivotto; Dobromir Dobrev; Michael J Ackerman; Xander H T Wehrens
Journal:  J Am Coll Cardiol       Date:  2013-08-21       Impact factor: 24.094

9.  A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.

Authors:  Rebecca C Coll; Avril A B Robertson; Jae Jin Chae; Sarah C Higgins; Raúl Muñoz-Planillo; Marco C Inserra; Irina Vetter; Lara S Dungan; Brian G Monks; Andrea Stutz; Daniel E Croker; Mark S Butler; Moritz Haneklaus; Caroline E Sutton; Gabriel Núñez; Eicke Latz; Daniel L Kastner; Kingston H G Mills; Seth L Masters; Kate Schroder; Matthew A Cooper; Luke A J O'Neill
Journal:  Nat Med       Date:  2015-02-16       Impact factor: 53.440

10.  IL-1 receptor antagonist ameliorates inflammasome-dependent inflammation in murine and human cystic fibrosis.

Authors:  Rossana G Iannitti; Valerio Napolioni; Vasilis Oikonomou; Antonella De Luca; Claudia Galosi; Marilena Pariano; Cristina Massi-Benedetti; Monica Borghi; Matteo Puccetti; Vincenzina Lucidi; Carla Colombo; Ersilia Fiscarelli; Cornelia Lass-Flörl; Fabio Majo; Lisa Cariani; Maria Russo; Luigi Porcaro; Gabriella Ricciotti; Helmut Ellemunter; Luigi Ratclif; Fernando Maria De Benedictis; Vincenzo Nicola Talesa; Charles A Dinarello; Frank L van de Veerdonk; Luigina Romani
Journal:  Nat Commun       Date:  2016-03-14       Impact factor: 14.919

View more
  123 in total

Review 1.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 2.  Inflammasomes and Proteostasis Novel Molecular Mechanisms Associated With Atrial Fibrillation.

Authors:  Na Li; Bianca J J M Brundel
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

3.  Inflammation, Inflammasome Activation, and Atrial Fibrillation.

Authors:  David R Van Wagoner; Mina K Chung
Journal:  Circulation       Date:  2018-11-13       Impact factor: 29.690

4.  A Miniaturized, Programmable Pacemaker for Long-Term Studies in the Mouse.

Authors:  Maarten Hulsmans; Aaron D Aguirre; Matthew D Bonner; Aneesh Bapat; Sebastian Cremer; Yoshiko Iwamoto; Kevin R King; Filip K Swirski; David J Milan; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

5.  Behçet's disease: A (silk) route to atrial fibrillation?

Authors:  Santosh V Suryavanshi; Na Li
Journal:  Int J Cardiol       Date:  2019-07-19       Impact factor: 4.164

6.  Pro-arrhythmic RyR2 channels in heart failure: do their localisation and mechanism of activation really matter?

Authors:  Dobromir Dobrev; Anke C Fender; Xander H T Wehrens
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

7.  Resveratrol: an effective pharmacological agent to prevent inflammation-induced atrial fibrillation?

Authors:  Henry Sutanto; Dobromir Dobrev; Jordi Heijman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-09-20       Impact factor: 3.000

Review 8.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

9.  Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction.

Authors:  Thassio Ricardo Ribeiro Mesquita; Rui Zhang; Geoffrey de Couto; Jackelyn Valle; Lizbeth Sanchez; Russell G Rogers; Kevin Holm; Weixin Liu; Eduardo Marbán; Eugenio Cingolani
Journal:  Heart Rhythm       Date:  2020-02-15       Impact factor: 6.343

Review 10.  Straight to the heart: Pleiotropic antiarrhythmic actions of oral anticoagulants.

Authors:  Anke C Fender; Reza Wakili; Dobromir Dobrev
Journal:  Pharmacol Res       Date:  2019-05-02       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.